publication date: Jan. 10, 2014


In Brief

Duke’s Gary Lyman to Co-Direct Fred Hutch Outcomes Research

GARY LYMAN was named co-director of The Hutchinson Institute for Cancer Outcomes Research, based at the Fred Hutchinson Cancer Research Center. He will co-lead with Scott Ramsey, a member of the Cancer Prevention Program in the Public Health Sciences Division at Fred Hutch.

Lyman served as professor of medicine and as a senior fellow at the Duke Center for Clinical Health Policy Research and Director of the Comparative Effectiveness and Outcomes Research Program in Oncology at the Duke Cancer Institute since 2007.

He will hold appointments within the Cancer Prevention Program, the Division of Medical Oncology at the University of Washington School of Medicine, and affiliate appointments within the Department of Health Services at the UW School of Public Health and in the UW School of Pharmacy. He will also practice as a medical oncologist in the Breast Cancer Program at Seattle Cancer Care Alliance.

Lyman is co-leading the development of comprehensive breast cancer and survivorship guidelines at the American Society of Clinical Oncology. He has served on numerous ASCO committees, and currently serves on the board of directors. He is also active with the American Society of Hematology and several other professional clinical and cancer research organizations.

GARY SCHWARTZ was named chief of the Division of Hematology/Oncology at NewYork-Presbyterian/Columbia University Medical Center. He will also serve as associate director for research of the Herbert Irving Comprehensive Cancer Center.

Previously, Schwartz was chief of the melanoma and sarcoma service at Memorial Sloan-Kettering Cancer Center, where he also … Continue reading 40-02 In Brief / FDA News

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.